Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5602329 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL5600191 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL5601695 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL4798376 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL5602384 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL5600182 | 1.00 | HRH4 (0.35) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL184035 | 0.98 | HRH4 (0.36) | HRH4KMT2AMIFCYP19A1KMO | |
| SCHEMBL5603196 | 0.93 | — | — | |
| SCHEMBL2820732 | 0.89 | — | — | |
| Pyrimidine SCHEMBL28478147 | 0.85 | CYP11B2 (0.36) | HRH4ALDH1A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298824-A1 | ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-10-03 | — | — | US | claimed |
| WO-2017192874-A1 | ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-09 | — | — | WO | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4739362-A1 | CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | Boston Scientific Scimed, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025226800-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250019500-A1 | CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2025010347-A1 | CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-20190298824-A1 | ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2017192874-A1 | ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-09 | — | — | WO | disclosed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332292-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH COVALENTLY ATTACHED DYE FOR MEDICAL APPLICATIONS | CD44, CRYAA, ILK | HRH4 2459/4885KMT2A 3238/4885MIF 272/4885 |
| US-20260144900-A1 | IN VIVO CROSSLINKABLE HYDROGELS WITH GOLD NANOPARTICLES FOR MEDICAL APPLICATIONS | KLK3, BPHL, BRDT | HRH4 1925/4885KMT2A 1586/4885MIF 1648/4885 |
| US-20190298824-A1 | ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF | ALB, CD74, CD47 | HRH4 2255/4885KMT2A 4265/4885MIF 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.